Probiotic Medilac-S® for the induction of clinical remission in a Chinese population with ulcerative colitis: A systematic review and meta-analysis

Table 1 Characteristics of included studies

Trial reference	Participants evaluated	Medication	Probiotic dose	Treatment duration	Follow-up period	Outcomes analyzed
Bu et al[31] 2017	68	Mesalazine	3.0 × 109 cfu/d	16 wk	NR	1, 6
Chen[32] 2007	47	SASP	3.0 × 109 cfu/d	12 wk	26 wk	1, 4, 5, 6
Chen[33] 2014	100	Mesalazine	3.0 × 109 cfu/d	6 wk	NR	1, 4
Chen et al[34] 2017	68	Mesalazine	3.0 × 109 cfu/d	8 wk	NR	1, 6, 7
Duan et al[35] 2015	64	SASP	3.0 × 109 cfu/d	4 wk	NR	2, 3, 6, 7
Gu[36] 2012	62	Mesalazine	3.0 × 109 cfu/d	12 wk	NR	1, 6
Guo and Sun[37] 2009	92	Mesalazine	3.0 × 109 cfu/d	12 wk	NR	1, 6
He et al[38] 2016	52	Mesalazine	3.0 × 109 cfu/d	12 wk	NR	1, 6
Jiang[39] 2013	110	Mesalazine	3.0 × 109 cfu/d	16 wk	52 wk	1, 5, 6
Jin et al[40] 2014	226	Mesalazine	3.0 × 109 cfu/d	12 wk	NR	1, 6
Li[41] 2011	62	Mesalazine	60 mg/d	12 wk	NR	1
Li[42] 2013	124	SASP	3.0 × 109 cfu/d	12 wk	NR	1, 6
Li[43] 2014	147	SASP	3.0 × 109 cfu/d	4 wk	NR	1
Li et al[44] 2006	50	SASP	3.0 × 109 cfu/d	12 wk	26 wk	1, 5
Li et al[45] 2016	100	Mesalazine	3.0 × 109 cfu/d	8 wk	NR	1, 4, 6
Liang et al[46] 2016	92	Mesalazine	3.0 × 109 cfu/d	16 wk	NR	1
Liu[47] 2014	62	SASP	3.0 × 109 cfu/d	4 wk	NR	1, 2, 3
Liu and Yao[48] 2012	139	Mesalazine	3.0 × 109 cfu/d	unknown	unknown	1, 5
Liu et al[49] 2009	43	SASP	3.0 × 109 cfu/d	8 wk	NR	1, 6
Liu and Li[50] 2014	101	Mesalazine	3.0 × 109 cfu/d	6 wk	NR	1, 2, 4
Luo[51] 2016	56	Mesalazine	3.0 × 109 cfu/d	8 wk	NR	1, 4, 6
Lu and Lei[52] 2011	132	Olsalazine	3.0 × 109 cfu/d	12 wk	NR	1, 6
Miao[53] 2014	72	Mesalazine	3.0 × 109 cfu/d	8 wk	26 wk	1, 5, 6
Meng[54] 2012	90	SASP	3.0 × 109 cfu/d	8 wk	NR	1, 2
Qin[55] 2015	56	Mesalazine	3.0 × 109 cfu/d	8 wk	NR	4
Qin et al[56] 2010	20	SASP	3.0 × 109 cfu/d	4 wk	NR	3, 7
Qin et al[57] 2010	64	Mesalazine	3.0 × 109 cfu/d	8 wk	26 wk	5, 6
Shen[58] 2014	96	Mesalazine	3.0 × 109 cfu/d	6 wk	NR	1, 4, 6
Su[59] 2015	120	Mesalazine	3.0 × 109 cfu/d	12 wk	NR	1, 6
Tan et al[60] 2008	20	SASP	3.0 × 109 cfu/d	4 wk	NR	2, 3, 6, 7
Tan et al[61] 2014	20	SASP	3.0 × 109 cfu/d	4 wk	NR	2, 3, 6, 7
Tang[62] 2008	104	SASP	3.0 × 109 cfu/d	4 wk	NR	1
Wang[63] 2013	84	Mesalazine	3.0 × 109 cfu/d	16 wk	52 wk	1, 5
Wang and Liu[64] 2007	36	SASP	3.0 × 109 cfu/d	4 wk	NR	1, 6
Wang and Li[65] 2014	100	Mesalazine	3.0 × 109 cfu/d	8 wk	NR	1, 2
Wang et al[66] 2016	65	Mesalazine	3.0 × 109 cfu/d	26 wk	NR	5, 6
Xiang and Feng[67] 2006	46	SASP	3.0 × 109 cfu/d	4 wk	NR	1, 4, 6
Xiao[68] 2014	63	SASP	3.0 × 109 cfu/d	8 wk	8 wk	5, 6
Xu[69] 2014	60	Balsalazide	3.0 × 109 cfu/d	12 wk	NR	1, 4, 6
Xu and Cui[70] 2009	56	Mesalazine	3.0 × 109 cfu/d	4 wk	NR	1
Yang[71] 2014	80	Mesalazine	3.0 × 109 cfu/d	Unknown	NR	1
Yang et al[72] 2008	52	SASP	3.0 × 109 cfu/d	4 wk	NR	1
Yuan et al[73] 2008	40	SASP	3.0 × 109 cfu/d	12 wk	26 wk	1, 4, 6
Zeng[74] 2008	49	SASP	3.0 × 109 cfu/d	12 wk	NR	1, 5
Zhang[75] 2013	78	SASP	3.0 × 109 cfu/d	4 wk	NR	1, 4, 6
Zhang[76] 2013	68	Olsalazine	3.0 × 109 cfu/d	12 wk	NR	1, 6
Zhang et al[77] 2010	54	Mesalazine	3.0 × 109 cfu/d	12 wk	NR	1
Zhang et al[78] 2016	70	Mesalazine	60 mg/d	12 wk	NR	1
Zhang et al[79] 2016	60	Mesalazine	3.0 × 109 cfu/d	12 wk	NR	1
Zhao and Zhang[80] 2016	62	Mesalazine	3.0 × 109 cfu/d	24 wk	NR	1
Zheng et al[81] 2016	118	Mesalazine	3.0 × 109 cfu/d	4 wk	NR	1, 6
Zhu et al[82] 2013	44	Olsalazine	3.0 × 109 cfu/d	96 wk	NR	2, 3
Zhuo et al[83] 2016	40	Mesalazine	3.0 × 109 cfu/d	8 wk	NR	1, 3, 6

Outcomes analyzed: (1) Clinical Efficacy; (2) Histological Assessment; (3) Endoscopy Assessment; (4) Clinical Symptoms; (5) Maintenance of Remission; (6) Adverse Events; (7) Sutherland Index. NR: Not reported.